Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage company focused on developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to two new employees. The awards, issued on August 30, 2024, consist of a total of 12,600 restricted stock units (RSUs). These grants were made under the company's 2024 Inducement Stock Incentive Plan and are in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in equal annual installments over a four-year period, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics. This move is part of the company's strategy to attract and retain talent in the competitive biotech sector.
Verve Therapeutics, un azienda in fase clinica focalizzata sullo sviluppo di medicinali genetici per le malattie cardiovascolari, ha annunciato la concessione di assegni azionari a due nuovi dipendenti. Gli assegni, emessi il 30 agosto 2024, consistono in un totale di 12.600 unità azionarie vincolate (RSU). Questi premi sono stati concessi nell'ambito del 2024 Inducement Stock Incentive Plan dell'azienda e sono conformi alla Regola di quotazione Nasdaq 5635(c)(4).
Le RSU si matureranno in rate annuali uguali nel corso di un periodo di quattro anni, a partire dal 1 ottobre 2024, a condizione che i dipendenti continuino a lavorare presso Verve Therapeutics. Questa mossa fa parte della strategia dell'azienda per attrarre e trattenere talenti nel competitivo settore biotech.
Verve Therapeutics, una empresa en etapa clínica centrada en el desarrollo de medicamentos genéticos para enfermedades cardiovasculares, ha anunciado la concesión de premios en acciones a dos nuevos empleados. Los premios, emitidos el 30 de agosto de 2024, consisten en un total de 12,600 unidades de acciones restringidas (RSU). Estas concesiones se realizaron bajo el 2024 Inducement Stock Incentive Plan de la empresa y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
Las RSU se adjudicarán en cuotas anuales iguales durante un periodo de cuatro años, comenzando el 1 de octubre de 2024, condicionado a la continuación del servicio de los empleados con Verve Therapeutics. Este movimiento es parte de la estrategia de la empresa para atraer y retener talento en el competitivo sector biotecnológico.
Verve Therapeutics는 임상 단계 회사로서 심혈관 질환을 위한 유전자 치료제 개발에 집중하고 있으며, 두 명의 신입 직원에게 주식 보상을 부여했다고 발표했습니다. 이 보상은 2024년 8월 30일에 발행되었으며, 총 12,600개의 제한 주식 단위(RSU)로 구성됩니다. 이러한 보상은 회사의 2024 유도 주식 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)을 준수합니다.
RSU는 4년 동안 동일한 연간 할부로 분배될 것이며, 2024년 10월 1일부터 직원들의 Verve Therapeutics에 대한 계속된 서비스에 따라 조건이 부여됩니다. 이는 경쟁이 치열한 생명공학 분야에서 인재를 유치하고 유지하기 위한 회사의 전략의 일환입니다.
Verve Therapeutics, une entreprise en phase clinique axée sur le développement de médecines génétiques pour les maladies cardiovasculaires, a annoncé l'octroi de récompenses en actions à deux nouveaux employés. Les récompenses, émises le 30 août 2024, se composent d'un total de 12 600 unités d'actions restreintes (RSU). Ces attributions ont été réalisées dans le cadre du 2024 Inducement Stock Incentive Plan de l'entreprise et sont conformes à la Règle de cotation Nasdaq 5635(c)(4).
Les RSU s'acquitteront par des versements annuels égaux sur une période de quatre ans, à partir du 1er octobre 2024, sous réserve de la poursuite du service des employés auprès de Verve Therapeutics. Ce mouvement fait partie de la stratégie de l'entreprise pour attirer et retenir les talents dans le secteur biotechnologique concurrentiel.
Verve Therapeutics, ein unternehmen in der klinischen Phase, das sich auf die Entwicklung von genetischen Medikamenten gegen Herz-Kreislauf-Erkrankungen konzentriert, hat die Gewährung von Aktienvergütungen an zwei neue Mitarbeiter angekündigt. Die Vergütungen, die am 30. August 2024 ausgegeben wurden, bestehen aus insgesamt 12.600 eingeschränkten Aktieneinheiten (RSUs). Diese Gewährungen erfolgten im Rahmen des 2024 Inducement Stock Incentive Plan des Unternehmens und entsprechen der Nasdaq-Listungsregel 5635(c)(4).
Die RSUs werden in gleichen jährlichen Raten über einen Zeitraum von vier Jahren fällig, beginnend am 1. Oktober 2024, abhängig von der kontinuierlichen Beschäftigung der Mitarbeiter bei Verve Therapeutics. Dieser Schritt ist Teil der Strategie des Unternehmens, Talente im wettbewerbsfähigen Biotech-Sektor zu gewinnen und zu halten.
- Verve Therapeutics is attracting new talent, potentially strengthening its workforce
- The company has a structured equity incentive plan in place for new employees
- None.
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024, the company granted equity awards to two new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received an aggregate of 12,600 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies, and for homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
How many restricted stock units (RSUs) did Verve Therapeutics (VERV) grant to new employees on August 30, 2024?
What is the vesting schedule for the RSUs granted by Verve Therapeutics (VERV) on August 30, 2024?
Under which plan did Verve Therapeutics (VERV) grant the inducement awards announced on September 3, 2024?
What Nasdaq rule does Verve Therapeutics (VERV) comply with for its inducement grants announced on September 3, 2024?
